Xintela expands and strengthens management team

Lund, Sweden, August 19, 2020 - Xintela announces it is expanding and strengthening its management team with Peter Ekolind as COO (Chief Operating Officer) and Thomas Areschoug as CBO (Chief Business Officer). Sven Kili, who has had a combined role as COO and CMO (Chief Medical Officer), will focus on his role as CMO.

“As Xintela's operations grow steadily and projects develop towards clinical studies and commercialisation, our organization also needs to grow. Given the exciting and eventful time we have ahead of us, it is extra stimulating to strengthen the company and welcome the new members of our management team”, says Xintela's CEO Evy Lundgren-Åkerlund.

Peter Ekolind has extensive experience of marketing, sales and leadership in several global pharmaceutical companies in various senior positions such as marketing- business area- and country manager. He has also been CEO of Getinge Sverige AB and the medtech company Avidicare AB. Since the beginning of the year, Peter has worked as a consultant for Xintela in business development. In his new role as COO, Peter will focus on marketing and communication and support Xinela's CEO in day-to-day as well as strategic management of Xintela's operations.

Thomas Areschoug, who has extensive experience in biomedical research and development as well as business development in Life Science, most recently came from a leading role at Business Sweden. Thomas previously spent 3 years in business development with Xintela. Thomas will continue to grow Xintela's business development focus by seeking new collaboration partners and licensees for the development and commercialization of the company's technologies in oncology and stem cell therapy for humans and animals. Thomas and Peter will join Xintela's senior management group together with the CEO, CFO and Chairman.

Sven Kili, who is an orthopedic surgeon and expert in cell and gene therapy, has previously had a combined role as both COO and CMO in Xintela. Sven will now focus on his role as CMO to support the company in its clinical development work. Xintela's selected stem cells XSTEM, are approaching clinical trials, where treatment of osteoarthritis is the first stem cell focus. Xintela is also evaluating XSTEM for the treatment of covid-19 patients with severe lung complications. Sven is a member of Xintela's board of directors.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].